2021
A Brewing Back Pain
Pischel L, Geirsson A, Magaldi J, Martinello RA, Lee AI. A Brewing Back Pain. New England Journal Of Medicine 2021, 385: 66-72. PMID: 34192434, PMCID: PMC9273048, DOI: 10.1056/nejmcps2034802.Peer-Reviewed Original ResearchRace and ethnicity do not impact eligibility for remdesivir: A single-center experience
Pischel L, Walelo M, Benson J, Osborn R, Schrier R, Tuan J, Barakat L, Ogbuagu O. Race and ethnicity do not impact eligibility for remdesivir: A single-center experience. PLOS ONE 2021, 16: e0250735. PMID: 33956849, PMCID: PMC8101938, DOI: 10.1371/journal.pone.0250735.Peer-Reviewed Original ResearchConceptsClinical trialsExclusion criteriaSingle health care systemObservational cohort studySingle-center experienceClinical trial criteriaTime of presentationMedical record chartsNon-Hispanic whitesEthnic minority enrollmentSimilar ratesHealth care systemCohort studyTrial criteriaMultiple therapiesInclusion criteriaRecord chartsEthnic groupsRemdesivirCare systemTrialsSelf-identified WhiteEligibilityWhite participantsMultiple potential barriers
2020
Diagnosis of oesophageal mucormycosis managed with medical therapy alone
Ringer M, Pischel L, Azar MM. Diagnosis of oesophageal mucormycosis managed with medical therapy alone. BMJ Case Reports 2020, 13: e236869. PMID: 33093060, PMCID: PMC7583061, DOI: 10.1136/bcr-2020-236869.Peer-Reviewed Original ResearchConceptsIdarubicin/cytarabineLiposomal amphotericin BAcute myeloid leukemiaFebrile neutropeniaInduction chemotherapyPosaconazole therapyClinical characteristicsMedical therapySurgical morbiditySurgical interventionAggressive infectionDevastating manifestationMyeloid leukemiaCT scanInvasive moldsMucormycosisLebanese menAmphotericin BPatientsDiagnosisTherapyReportOdynophagiaNeutropeniaThrombocytopeniaTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes